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The bovine papillomavirus type 1 (BPV-1) E6 oncoprotein induces tumorigenic transformation of murine C127 cells and
stimulates transcription when targeted to a promoter. We have previously shown that C127 cells expressing BPV-1 E6
exhibited increased tumor necrosis factor  (TNF)-mediated apoptosis. To understand the mechanisms by which BPV-1 E6
sensitizes cells to apoptosis and to investigate the relevance of E6-enhanced apoptosis to its other biological activities, we
analyzed a BPV-1 E6 mutant (491, with four amino acids deleted at the C-terminus) for its ability to sensitize C127 cells to
apoptosis. The result was then compared with the E6 mutant’s ability to transform cells, to activate transcription, and to
associate with known cellular binding proteins. Our data indicated that the transcriptional activation function of BPV-1 E6
correlated with sensitization of cells to TNF-mediated apoptosis. Moreover, functions required for BPV-1 E6-mediated
sensitization of cells to apoptosis are distinct from those required for transformation. A potential role of paxillin in E6
sensitization of cells to apoptosis is implicated. These results thus indicate that sensitization of cells to TNF-inducedElsevie
ranscriINTRODUCTION
Papillomaviruses (PV) are small DNA viruses that in-
fect various epithelial tissues. Some animal PVs, includ-
ing BPV-1, also induce fibropapillomas. Specific types
(“high-risk”) of human papillomaviruses (HPV) infect the
anogenital tract and are strongly associated with the
development of cervical carcinoma (for review, see zur
Hausen, 1996). Because of its ability to replicate its
genome in established murine cell lines and to induce
cellular transformation, BPV-1 had served as the proto-
type for studies of the molecular biology of the papillo-
maviruses before recent interest switched to the study of
HPV (for review, see Howley, 1996).
The transforming properties of BPV-1 primarily reside
in two genes, E5 and E6. Each of these genes is suffi-
cient to induce anchorage-independent growth and fo-
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230cus formation of murine C127 cells (DiMaio et al., 1986;
Dvoretzky et al., 1980; Groff and Lancaster, 1986; Lowy et
al., 1980; Schiller et al., 1984, 1986; Schlegel et al., 1986).
BPV-1 E6-transformed C127 cells form tumors in nude
mice (Schiller et al., 1984). The BPV-1 E6 oncogene prod-
uct is a 137-amino-acid protein with two putative zinc
finger motifs that are conserved among all papillomavi-
rus E6 proteins. The mechanism of BPV-1 E6-induced
cellular transformation is not known. Although E6 pro-
teins from high-risk HPVs bind and promote the degra-
dation of the tumor suppressor protein p53, BPV-1 E6
does not (Werness et al., 1990). We identified a calcium-
binding protein, E6BP (or ERC-55), as a cellular associ-
ating protein for BPV-1 E6 as well as high-risk HPV E6s
(Chen et al., 1995). The transforming activity of a set of
previously characterized BPV-1 E6 mutants correlated
with their E6BP-binding ability, suggesting that this inter-
action may play an important role in BPV-1 E6-mediated
transformation. BPV-1 E6 also efficiently binds E6AP
(Chen et al., 1995), the cellular protein through which
HPV-16 E6 stimulates ubiquitination and degradation of
p53. However, a candidate degradation cellular target for
a potential BPV-1 E6/E6 AP complex has not been iden-
tified. Interactions of BPV-1 E6 protein with the focal
adhesion-associated protein paxillin and the  subunit of
the trans-Golgi network-specific clatharin adaptor (AP-1)apoptosis represents a novel function of BPV-1 E6. © 2002
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ptional activation.
complex have been described (Das et al., 2000; Tong and
Howley, 1997; Tong et al., 1998; Vande Pol et al., 1997). Iton
appears that paxillin interaction with E6 is necessary but
not sufficient for C127 cell transformation. Recently, it
was shown that BPV-1 E6 bound the transcriptional co-
activator CBP/p300 (Zimmermann et al., 2000). This in-
teraction may lead to the down-regulation of CBP/p300-
mediated transactivation in a way independent of p53
degradation.
BPV-1 E6 stimulates transcription when targeted to a
promoter (Lamberti et al., 1990), although cellular pro-
moters responsive to BPV-1 E6 have not been identified.
Mutational analysis has indicated that the transcriptional
activation function of BPV-1 E6 is not sufficient for cell
transformation (Chen et al., 1997; Ned et al., 1997). Fur-
thermore, the identification of a transformation compe-
tent mutant with greatly reduced transcriptional activa-
tion activity raised the possibility that transformation by
BPV-1 E6 is independent of its transcriptional activation
function (Ned et al., 1997).
Many viral as well as cellular oncogenes have been
shown to be involved in the modulation of apoptosis
(Shen and Shenk, 1995), a genetically programmed pro-
cess of self-destruction representing an integral compo-
nent of normal cellular maintenance (Kerr and Harmon,
1992). Apoptosis serves to eliminate aberrantly prolifer-
ating or virally infected cells that may threaten the sur-
vival of the organism. In the case of virally infected cells,
this early cell death inhibits viral replication and produc-
tion of progeny virus (Hardwick, 1997). On the other hand,
many lytic animal viruses have evolved specific gene
products that interfere with premature death, allowing
production of high levels of progeny virus (for review, see
Shen and Shenk, 1995; Teodoro and Branton, 1997). The
viral antiapoptotic function, coupled with the growth pro-
moting functions, can contribute to uncontrolled growth
and oncogenesis. TNF is a 17-kDa inflammatory cytokine
that mediates a variety of immune and inflammatory
reactions (Tracey and Cerami, 1993). Some tumor cell
lines are sensitive to TNF, but most cell lines are resis-
tant (Carswell et al., 1975; Sugarman et al., 1985). Infec-
tion with some virus types, such as adenovirus, induces
susceptibility to the cytotoxic effect of TNF (Chen et al.,
1987; Deurksen-Hughes et al., 1989). C127 cells are sen-
sitive to TNF in the presence of metabolic inhibitors or
some viral proteins (Bergovist et al., 1997; Carswell et al.,
1975; Gooding et al., 1991). Some BPV-1-transformed
C127 cells were shown to have increased TNF sensitivity
(Bergovist et al., 1997; Rapp et al., 1999).
We have reported that expression of BPV-1 E6 sensi-
tizes cells to TNF-induced apoptosis (Rapp et al., 1999).
In the present study, we analyzed the BPV-1 E6 mutant
491 for its ability to sensitize cells to apoptosis, to trans-
form cells, to activate transcription, and to interact with
known cellular binding proteins. Our results indicate that
sensitization to apoptosis does not correlate with trans-
formation capability and therefore may represent an in-
dependent activity of BPV-1 E6.
RESULTS
We had previously described the establishment of cell
lines that express BPV-1 E6 (PBE6), BPV-1 E6 mutant 359
(PB359), and the retrovirus vector pBabe Puro (PURO)
(Rapp et al., 1999). To extend this study, a cell line that
expresses BPV-1 E6 mutant 491 was established. The
mutant 491 has four amino acid residues deleted from
the C-terminus of E6 (serine134 to stop). Previous studies
showed that 491 was defective in cellular transformation
but competent for transcriptional activation (summarized
in Table 1 and Chen et al., 1997). To facilitate the detec-
tion of E6 proteins, cell lines expressing the Escherichia
coli LexA DNA-binding domain (LexA202) and LexA-
BPV-1 E6 chimeric proteins (both wild-type and mutant
491) were also established. To make these cell lines,
C127 cells were infected with amphotrophic retroviruses
containing BPV-1 E6 mutant 491 or LexA constructs. After
puromycin selection, populations of infected cells were
pooled and used for subsequent experiments. Cell lines
were designated by the names of mutants or genes
preceded by P or PB (for puromycin-resistant or puromy-
cin-resistant BPV-1 E6). A total of four cell lines were
established; these are PB491, PLexA, PLexABE6, and
PLexAB491 (Table 2). To avoid the possibility of chromo-
somal instability due to the expression of BPV-1 E6, all
experiments described here were performed using cells
within 12 passages.
Morphologically, PB491 cells at low density remained
flat and were indistinguishable from PURO cells (Fig. 1A).
In contrast, PBE6 cells became spindle shaped (Fig. 1A).
Within 24 h of confluence, PBE6 piled up and became
highly spindle shaped, indicating a loss of contact inhi-
TABLE 1
Summary of BPV-1 E6 Mutant Studies
Name Mutation Apoptosisa Transformationa Transactivationa E6AP bindinga E6BP bindinga Paxillin bindinga
Control N/Ab      
wt None      
491 Ser134 to stop      
a Data from multiple experiments are summarized as follows (wild-type E6 activity  100%): () 81 to 100%; () 16%; () 5%.
b N/A, not applicable.
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bition, as observed in focus formation assays with BPV-1
E6 (Fig. 1B). In contrast, PB491 or the control PURO cells
grew to only a limited density (Fig. 1B). The PLexA,
PLexABE6, and PLexAB491 cells resemble PURO, PBE6,
and PB491 at both low and high densities, respectively
(data not shown). These data are consistent with previ-
ous results that mutant 491 and LexAB491 were defective
for transformation (Chen et al., 1997; Vousden et al.,
1989).
To examine the expression of BPV-1 E6 proteins, an-
tisera against BPV-1 E6 were used in an immunoprecipi-
tation experiment. Similar to what we observed previ-
ously (Rapp et al., 1999), wild-type BPV-1 E6 protein was
detected at a very low level in PBE6 cells, indicating that
the BPV-1 E6 protein level was in the physiologic range
and overexpression of the protein did not occur (data not
shown). The level of 491 was somewhat reduced com-
pared with that of the wild-type E6 (data not shown).
These results are also similar to the protein levels seen
in stable cell lines transfected with E6 (Vousden et al.,
1989). Nevertheless, functional studies indicate that both
wild-type and mutant E6 proteins are expressed (see
below). To quantify expression levels of the E6 proteins
further, we used anti-LexA antibody to detect LexA-
tagged wild-type and mutant E6 proteins after transfec-
tion into C127 cells. As shown in Fig. 2, as with LexA
fusion proteins, the expression level of mutant 491 was
similar to that of the wild-type E6.
To evaluate the effect of mutant 491 on cell death, the
E6-expressing cells were treated with murine TNF and
TABLE 2
Cell Lines Used in This Study
Name Gene expressed
PURO None
PLexA LexA202
PBE6 BPV-1 E6
PLexABE6 LexA202-BPV-1 E6
PB491 BPV-1 E6 mutant 491
PLexAB491 LexA202-BPV-1 E6 mutant 491
Note. All cell lines contain the pBabe Puro vector.
FIG. 1. Characterization of cells expressing BPV-1 E6. (A) Morphology of BPV-1 E6-expressing cells. (B) Contact inhibition in cells expressing BPV-1
E6 mutant 491. PBE6 grew to a higher density than PURO and PB491. Photographs were taken approximately 24 h after cells became confluent.
FIG. 2. Expression of LexA-BPV-1 E6 proteins. [35S]cysteine- and
[35S]methionine-labeled cell lysates were subjected to immunoprecipi-
tation using a monoclonal antibody against LexA. The position of
LexA-BPV-1 E6 is indicated by an arrow. LexA or LexA-E6 fusions are
indicated above each lane.
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cell viability was determined quantitatively by analysis of
MTT conversion (Hansen et al., 1989). As shown in Fig. 3
and summarized in Table 1, PB491 cells exhibited a
wild-type E6 level of cytolysis after TNF induction, which
is severalfold over that of PURO control cells. To dem-
onstrate that LexA-E6 is competent for the sensitization
of cells to cytolysis, cell lines expressing LexA, LexA-
BPV-1 E6, and LexA mutant 491 were also characterized.
Our results demonstrated that like native BPV-1 E6 and
mutant 491, both LexA-BPV-1 E6 and LexA-B491 also
sensitized C127 cells to TNF-induced cytolysis (Fig. 3).
The TNF-induced lysis of susceptible cells is usually
accompanied by the release of arachidonic acid into the
culture medium (Hayakawa et al., 1993). Previously we
reported that PBE6 cells exhibited a greater increase in
released arachidonic acid after TNF treatment compared
with PURO cells (Rapp et al., 1999). Here we examined
the release of arachidonic acid from mutant 491-express-
ing cells in the response to TNF. As expected, sensitiza-
tion of mutant 491-expressing cells to TNF-induced cy-
tolysis correlated with the increased release of arachi-
donic acid (data not shown).
TNF kills most cell types by apoptosis rather than
necrosis (Laster et al., 1988). We have previously dem-
onstrated that PBE6 cells undergo apoptosis after TNF
treatment (Rapp et al., 1999). To examine if the cytolysis
of cells expressing mutant 491 after TNF treatment is
apoptotic, we performed the Cell Death Detection
ELISAplus assay on PB491 and PLexA491 cells. This assay
provides a qualitative and quantitative determination of
cytoplasmic histone-associated DNA fragments result-
ing from DNA degradation that occurs specifically in
apoptotic cells. During the process of apoptosis, specific
cellular proteases and endonucleases are activated and
cellular DNA is degraded to characteristic nucleosome-
sized fragments. As shown in Fig. 4, treatment of PBE6
and PB491 cells with TNF for 24 h resulted in specific
enrichment of mono- and oligonucleosomes released
into the cytoplasm. An approximately 2.5-fold enrichment
of nucleosomes in cytoplasm was observed in both
PBE6 and PB491 cells compared with PURO cells. While
PLexABE6 cells demonstrated a similar fold increase in
apoptosis compared with PBE6 cells, PLexAB491 cells
exhibited a modest but statistically significant increase
compared with PLexA cells (P  0.05). These results
indicate that, similar to wild-type E6 cells, cells express-
ing mutant 491 undergo enhanced apoptosis after TNF
treatment.
FIG. 4. Induction of apoptosis by TNF in BPV-1 E6 mutant-expressing
cells. Subconfluent proliferating BPV-1 E6 mutant-expressing cells or
control cells were treated with 10 ng/ml of TNF for 24 h. Cell lysates
were analyzed for nucleosomes in cytoplasmic fractions by the Cell
Death Detection ELISAplus kit. Data shown represent the average of
three independent experiments. Error bars reflect the standard devia-
tions of the mean.
FIG. 3. Sensitization of BPV-1 E6-expressing cells to TNF treatment.
Murine C127 cells expressing E6 mutant 491 showed sensitization to
TNF-induced cytolysis. BPV-1 E6 mutant-expressing cells or control
PBE6 and PURO cells were treated with 10 ng/ml of mouse TNF. Cell
viability was determined 48 h later by analysis of MTT conversion.
Values represent the mean of results from three independent experi-
ments. Error bars represent the standard deviations of the mean.
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We had previously shown that BPV-1 E6 sensitization
of cells to apoptosis could occur in the absence of p53.
In the present study, we examined the potential roles of
other E6-binding proteins in this process. We previously
characterized mutant 491 for interaction with E6AP and
E6BP (Chen et al., 1997). Here we examined the associ-
ation of mutant 491 with paxillin in an in vitro experiment.
For this purpose, GST-paxillin and in vitro translated
BPV-1 E6 mutant 491 were prepared. GST, GST-E6AP,
GST-E6BP, and GST-E6APdl were used as controls.
E6APdl is a mutant of E6AP containing a deletion in its
E6-binding motifs and does not bind wild-type E6
(Huibregtse et al., 1993). In vitro translated wild-type
BPV-1 E6 and mutant 359 were also included as controls.
Mutant 359 was defective for sensitizing cells to TNF-
mediated cytolysis and association with E6AP, E6BP, and
paxillin (Chen et al., 1995; Rapp et al., 1999; Tong and
Howley, 1997). These results are summarized in Table 1
and shown in Fig. 5. Consistent with our previous obser-
vation, mutant 491 did not bind efficiently to E6AP and
E6BP, suggesting that these interactions may not be
important for apoptosis. Interestingly, binding of 491 with
paxillin correlated with E6 sensitization to TNF-induced
apoptosis, suggesting a potential role of paxillin in
apoptosis.
Transcriptional activity is important in some onco-
gene- and tumor suppressor-mediated apoptosis. For
example, p53 transcriptional activity is essential for p53-
dependent apoptosis following DNA damage (Chao et
al., 2000). We therefore investigated if the transcriptional
activation function of BPV-1 E6 was required for its ability
to sensitize cells to apoptosis. For this purpose, the
ability of mutant 491 to stimulate transcription was com-
pared with its ability to sensitize cells to apoptosis. As
the cellular promoters responsive to BPV-1 E6 have not
been identified, we had previously established an assay
to examine the intrinsic transcriptional activity of BPV-1
E6. BPV-1 E6 and mutant 491 as LexA fusions used in
this study were analyzed for transcriptional activity in
both yeast and mammalian cells (Chen et al., 1997). As
summarized in Table 1, both the wild-type BPV-1 E6 and
mutant 491 are active in transcriptional activation. This
result indicates that the transcriptional activation func-
tion of BPV-1 E6 correlates with sensitization of cells to
apoptosis.
Next we analyzed if the transforming activity of BPV-1
E6 is important for sensitizing cells to apoptosis. Our
previous data demonstrated that LexA-BPV-1 E6, like
authentic BPV-1 E6, was competent for C127 cell trans-
formation (Chen et al., 1997). In contrast, mutant 491 and
LexAB491 were essentially defective for transformation.
This is consistent with the lack of contact inhibition
phenotype of PB491 and PLexAB491 cells (Fig. 1B).
These results indicate that E6-mediated apoptosis sen-
sitization can occur in the absence of cellular transfor-
mation, although we cannot rule out the possibility that
sensitization to apoptosis is necessary for transforma-
tion.
DISCUSSION
Cytokines such as TNF, Fas ligand, and TRAIL are
produced by cells in response to a viral infection. These
cytokines can elicit a wide spectrum of cellular re-
sponses, including apoptosis. Viruses, on the other
hand, have evolved gene products that modulate cyto-
kine-induced apoptotic activity (for review, see Teodoro
and Branton, 1997). For example, opposing effects on
TNF- and Fas-mediated apoptosis have been observed
for the adenovirus E3-10.4K/14.5K complex and E1A
(Duerksen-Hughes et al., 1989; Shisler et al., 1997; Wold
and Gooding, 1989). Interestingly, HPV-16 E7 sensitizes
human keratinocytes to TNF- and TRAIL-mediated apo-
ptosis (Basile et al., 2001), while it inhibits normal human
diploid fibroblasts from undergoing apoptosis in re-
sponse to TNF and Fas treatment (Jones et al., 1997;
Thompson et al., 2001). Recently, the mechanisms by
which viral genes modulate apoptosis have begun to be
understood. The adenovirus E3-10.4K/14.5K complex
blocks surface Fas expression to inhibit Fas-mediated
apoptosis (Elsing and Burgert, 1998; Shisler et al., 1997;
Tollefson et al., 1998). HPV-16 E7 interferes with caspase
FIG. 5.Mutational analysis of BPV-1 E6 association with E6-AP, E6BP,
and paxillin. Glutathione Sepharose beads containing GST-E6AP, GST-
E6BP, GST-paxillin, or control GST fusion proteins were combined with
35S-labeled in vitro translated wild-type or mutant 491 proteins. After
incubation and washes, the bound products were separated by SDS–
polyacrylamide gel electrophoresis and analyzed by Molecular Imager.
The E6 proteins are indicated above each lane. GST fusion proteins are
indicated to the left. E6APdl is an E6AP mutant that contains an
18-amino-acid deletion. Input was a direct loading of 10% of the
[35S]cysteine-labeled E6 proteins used in each binding reaction.
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8 activation to inhibit TNF-mediated apoptosis (Thomp-
son et al., 2001). Moreover, the ability of E7 to undermine
TNF-mediated apoptosis in normal human diploid fibro-
blasts correlated with cellular transformation (Thompson
et al., 2001). Here we examined the mechanisms
by which BPV-1 E6 sensitizes cells to TNF-mediated
apoptosis.
It is believed that inappropriate activation of cell cycle
progression by oncogenes results in protective response
by the cells, which ultimately leads to apoptosis. The
ability of oncogenes to induce cell growth is not readily
separable from the ability to promote programmed cell
death. For example, although there is evidence that
c-Myc-induced cell proliferation and apoptosis can be
separated on the basis of effector pathways, structure–
function analysis illustrated complete genetic overlap
(reviewed in Prendergast, 1999). We examined the wild-
type and the previously studied mutant 491 in the apo-
ptosis assays. Our results indicate that BPV-1 E6-in-
duced sensitization to TNF-mediated apoptosis can oc-
cur in the absence of cellular transformation. This
striking result raises interesting questions about the ac-
tion of BPV-1 E6. Further studies are needed to delineate
the mechanisms by which E6 sensitizes cells to apopto-
sis.
Correlation of the transcriptional activation function of
BPV-1 E6 with sensitization of cells to apoptosis raises
the possibility that E6 may up-regulate the expression of
apoptosis-related genes. The TNF receptor (TNFR1) is a
candidate gene. However, our preliminary studies exam-
ining TNFR1 expression did not reveal any significant
change in E6-expressing cells compared with control
cells (data not shown). Similar to the model proposed for
c-Myc-induced apoptosis (Green, 1997), BPV-1 E6 may
repress the transcription of an inhibitor(s) of TNF-in-
duced apoptosis. It would be interesting to identify such
inhibitors.
To further characterize the BPV-1 E6-induced sensiti-
zation to apoptosis, we examined the correlation be-
tween this activity and association with cellular proteins.
While interactions with E6AP and E6BP do not appear to
be necessary for E6-mediated sensitization to apoptosis,
a correlation with paxillin association was observed.
Although no direct involvement of paxillin in apoptosis
has been reported, antiapoptotic activities have been
observed for the paxillin-associated focal adhesion ki-
nase (FAK) (Chan et al., 1999), and references therein.
The E6–paxillin interaction may contribute to the disas-
sembly of focal adhesion complexes and thereby inter-
fere with survival signals from the extracellular matrix.
However, in contrast to our in vitro results, the apoptosis
sensitization-competent mutant 491 did not bind paxillin
in a transient transfection assay (Tong and Howley,
1997). It is not clear whether the in vitro assay or a
transfection assay can truly reflect the in vivo situation.
The significance of interaction with paxillin in sensitizing
cells to apoptosis by E6 remains to be established.
MATERIALS AND METHODS
Plasmids
The retroviral vector pBabe Puro is a Moloney murine
leukemia virus-based vector containing a puromycin re-
sistance gene (Morgenstern and Land, 1990). LexA202
(Gyuris et al., 1993) and LexA-BPV-1 E6 mutant 491 were
subcloned into pBabe Puro.
Plasmids encoding wild-type BPV-1 E6, mutant 491,
and LexA-BPV-1 E6 in pBabe Puro (Chen et al., 1997;
Rapp et al., 1999); wild-type BPV-1 E6 and mutant 491 in
pSP65 vector (Chen et al., 1995); wild-type BPV-1 E6 and
mutant 491 as LexA fusion proteins in pcDNA3 (Chen et
al., 1997); GST-E6BP-211 (Chen et al., 1995); GST-E6BPdl
(deletion of amino acids 194–217) (Chen et al., 1998);
GST-paxillin (Tong and Howley, 1997); GST-E6AP;
and GST-E6APdl (deletion of amino acids 391–401)
(Huibregtse et al., 1993) were described previously.
Cell culture
C127 is a nontransformed clonal line derived from the
mammary tissue of an RIII mouse (Lowy et al., 1978). To
establish stable BPV-1 E6-expressing cells, plasmids en-
coding mutant 491, LexA-BPV-1 E6, and LexA-491 in the
pBabe Puro vector were transfected into the ampho-
tropic retrovirus packaging cell line PA317 (Miller and
Buttimore, 1986) by calcium phosphate-mediated trans-
fection. Transfected cells were selected for puromycin
resistance. Viruses were collected and titered on C127
cells to determine the puromycin-resistant colony form-
ing units (CFU). C127 cells were then infected with ret-
roviruses containing approximately equal CFU. After pu-
romycin selection, populations of infected cells were
pooled and used for subsequent experiments. All exper-
iments were performed using cells within 12 passages.
Colorimetric MTT assay and Cell Death Detection
ELISAPlus
For cytolysis and apoptosis analysis, cells were
seeded in 96-well plates at a density of 1  103 cells per
well. The following day, all media were changed, with
some cells treated with murine recombinant TNF (Sigma,
St. Louis, MO) as indicated. To examine cell survival,
cells were measured using the quantitative colorimetric
MTT assay kit (Chemicon Int. Inc., Temecula, CA) according
to the manufacturer’s protocol. MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-2H-tetrazolium bromide) is cleaved by liv-
ing cells to yield a dark blue formazan product. Plates were
analyzed in an ELISA plate reader at 570 nm with a refer-
ence wavelength of 655 nm. For apoptosis study, 20 of 200
l extracts collected from each well were used for analysis
of nucleosomes in cytoplasmic fractions using the Cell
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Death Detection ELISAplus kit (Boehringer Mannheim Corp.,
Indianapolis, IN). Enrichment factor represents the absor-
bence at 405 nmwith a reference of 492 nm for treated cells
divided by the corresponding untreated cells.
Protein preparation and association experiments
Glutathione S-transferase (GST) fusion proteins were
prepared as described (Liu et al., 2000). E6 proteins were
translated in vitro by using the rabbit reticulocyte lysate
translation system (Promega) in the presence of 35S-
labeled cysteine (ICN Biomedicals, Irvine, CA).
For in vitro binding, 30 l of glutathione Sepharose
containing 2 g of GST fusion proteins were combined
with 2–20 l of 35S-labeled in vitro translated proteins in
lysis buffer (250 mM NaCl, 20 mM Tris–HCl (pH 7.4), 0.5%
Nonidet P-40, 1 mM EDTA, 2 mM DTT, and 1 mM PMSF)
in a total volume of 250 l. The mixtures were subjected
to rotary shaking for 3 h at 4°C. The mixtures were then
washed extensively with lysis buffer, boiled in SDS sam-
ple buffer, and electrophoresed on SDS–polyacrylamide
gels. Gels were dried and scanned by Molecular Imager
(Bio-Rad).
Immunoprecipitation assays
To detect E6 proteins, proliferating cells were meta-
bolically labeled overnight with 0.9 mCi of [35S]cysteine
per 10-cm dish in cysteine-free Dulbecco’s minimum
essential medium containing 2% dialyzed fetal calf se-
rum. Cells were lysed at 4°C in 500 l of lysis buffer.
Insoluble debris was pelleted at 10,000 g for 30 min and
the supernatant incubated with anti-BPV-1 E6 antiserum
(P-18, Androphy et al., 1985) and protein A–Sepharose
beads. After extensive washes with lysis buffer, the
bound proteins were released from the beads by boiling
in SDS sample buffer and loaded onto a 15% SDS–
polyacrylamide gel. The BPV-1 E6 band was analyzed by
Personal Molecular Imager FX (Bio-Rad).
To detect LexA-BPV-1 E6 proteins, C127 cells were
transfected plasmids encoding LexA or LexA-BPV-1 E6 in
pcDNA3 using FuGENE 6 Transfection Reagent. Thirty-
six hours posttransfection, cells metabolically labeled
overnight with [35S]cysteine and [35S]methionine. Cell ex-
tracts were prepared by lysing cells with lysis buffer that
contained 1% NP-40 and 0.1% SDS. Lysates containing
equal cpm were immunoprecipitated with anti-LexA an-
tiserum (SC-1725, Santa Cruz Biotechnology). Following
extensive wash, the bound proteins were subjected to
SDS–PAGE on a 15% gel and analyzed by Personal Mo-
lecular Imager FX.
Statistical methods
Student’s t test was used to assess the statistical
significance of differences in E6-expressing cells and
control cells. P  0.05 was considered significant.
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